Editas Medicine Inc. (EDIT) Stock
Fundamentals
Recent news

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
EDIT

Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
EDIT

Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401
EDIT

Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
EDIT
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.22 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
EDIT

Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
EDIT

Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401
EDIT

Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
EDIT

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
EDIT

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
EDIT

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates
Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates
EDIT

Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?
Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?
EDIT

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
EDIT

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
EDIT
About Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Gilmore O'Neill M.D. | President, CEO & Director | 1964 |
| Ms. Amy Parison | Senior VP & CFO | 1986 |
| Dr. Linda C. Burkly Ph.D. | Executive VP & Chief Scientific Officer | 1957 |
| Dr. Feng Zhang Ph.D. | Co-Founder & Scientific Advisory Board Member | — |
| Dr. George McDonald Church Ph.D. | Co-Founder & Scientific Advisory Board Member | 1954 |
| Mr. Gregory Whitehead | Executive VP and Chief Technical & Quality Officer | — |
| Mr. Damien Grierson J.D. | Senior VP, General Counsel & Corporate Secretary | — |
| Mr. Tom Love | Vice President of People | — |
| Mr. Frank Panaccio | Senior VP & Chief Business Officer | — |
| Ms. Brieana Buckley | Senior Vice President of Development and Program Leadership | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
1 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -3.3 | -8.0 | -15.4 | -12.7 | ||||||||
| 2022 | -31.1 | -13.1 | +8.7 | -34.5 | -20.2 | +7.8 | +26.4 | -7.2 | -20.6 | +1.8 | -16.9 | -11.8 |
| 2023 | +17.2 | -13.2 | -16.9 | +15.3 | +10.6 | -13.8 | +6.6 | +3.0 | -14.1 | -6.4 | +52.6 | -5.9 |
| 2024 | -29.6 | +39.3 | -29.5 | -28.4 | -4.9 | -13.7 | +17.4 | -27.2 | -2.3 | -11.3 | -23.0 | -42.0 |
| 2025 | +0.0 | +51.2 | -34.5 | +46.0 | +6.2 | +24.3 | +11.6 | +5.3 | +40.5 | -13.2 | -21.2 | -6.4 |
| 2026 | -2.9 | +9.5 | +14.9 | +14.9 | +19.3 | -3.0 | -21.3 | +15.5 | -16.0 |



